Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
At a glance
- Drugs SRX 246 (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- 03 Nov 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2030.
- 03 Nov 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2030.
- 09 Mar 2017 Status changed from not yet recruiting to recruiting.